Ben Gil Price, Director at REXAHN PHARMACEUTICALS, INC. (RNN), bought 15,000 shares at $0.61 ($9K) on 2019-01-29, disclosed to the SEC on 2019-01-31.
Open-market purchase of $9k RNN by Director. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade B.
Something here stands out, but not much.
| Filing → |
| AVII | BUY | 2012-03-15 | $39K | — | Filing → |
| AVII | BUY | 2011-04-06 | $30K | — | Filing → |
| AVII | BUY | 2010-08-16 | $8K | — | Filing → |